Kenneth Marek
A5091194111- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Medical Imaging Techniques and Applications
- Alzheimer's disease research and treatments
- Nuclear Receptors and Signaling
- Autism Spectrum Disorder Research
- Genetic Neurodegenerative Diseases
- Botulinum Toxin and Related Neurological Disorders
- Advanced MRI Techniques and Applications
- Neurological diseases and metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Dementia and Cognitive Impairment Research
- Neuroscience and Neuropharmacology Research
- Olfactory and Sensory Function Studies
- Advanced Neuroimaging Techniques and Applications
- Traumatic Brain Injury Research
- Functional Brain Connectivity Studies
- Lysosomal Storage Disorders Research
- Lanthanide and Transition Metal Complexes
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Restless Legs Syndrome Research
- Phosphodiesterase function and regulation
- Receptor Mechanisms and Signaling
- Computational Drug Discovery Methods
Institute for Neurodegenerative Disorders
2016-2025
University of Pennsylvania
2014-2024
University of Iowa
2017-2024
Elucid Bioimaging
2014-2024
Invicro (United States)
2018-2024
Konica Minolta (United States)
2021-2024
Invicro (United Kingdom)
2024
Northwestern University
2024
Indiana University – Purdue University Indianapolis
2024
Inha University
2024
The clinical data suggest that levodopa either slows the progression of Parkinson's disease or has a prolonged effect on symptoms disease.In contrast, neuroimaging accelerates loss nigrostriatal dopamine nerve terminals its pharmacologic effects modify transporter.The potential long-term remain uncertain.
<h3>Background</h3> The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. <h3>Objective</h3> To compare initial treatment with pramipexole vs levodopa in disease, followed by supplementation, respect the development of motor complications, other adverse events, and functional quality-of-life outcomes. <h3>Design</h3> Multicenter, parallel-group, double-blind, randomized controlled trial. <h3>Setting</h3> Academic movement disorders clinics at 22 sites...
Parkinson's disease is characterized by the loss of midbrain dopamine neurons that innervate caudate and putamen. Studies in animals suggest fetal dopaminergic can survive transplantation restore neurologic function. This report compares clinical results four case patients with severe who underwent stereotaxic implantation human ventral mesencephalic tissue one nucleus a control group similar subjects assigned at random to one-year delay surgery.
Abstract Objective The Parkinson's Progression Markers Initiative ( PPMI ) is an observational, international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, genetic, biospecimen disease PD progression markers accelerate disease‐modifying therapeutic trials. Methods A total of 423 untreated , 196 Healthy Control HC 64 SWEDD (scans without evidence dopaminergic deficit) subjects were enrolled at 24 sites. To enroll as early possible following diagnosis,...
<h3>Importance</h3> We observed a significant correlation between cerebrospinal fluid (CSF) levels of tau proteins and α-synuclein, but not β-amyloid 1-42 (Aβ1-42), lower concentration CSF biomarkers, as compared with healthy controls, in cohort entirely untreated patients Parkinson disease (PD) at the earliest stage studied so far. <h3>Objective</h3> To evaluate baseline characteristics relationship to clinical features biomarkers (Aβ1-42, total [T-tau], phosphorylated threonine 181...
<h3>Objective</h3> To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to reduced risk Parkinson disease (PD), predicts prognosis in PD. <h3>Design</h3> Prospective study. <h3>Setting</h3> The Research Examination CEP-1347 Trial (PRECEPT) study, which investigated the effects potential neuroprotectant on rates PD progression, was conducted between April 2002 August 2005 (average follow-up time 21.4 months). <h3>Participants</h3>...
Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on
Early identification of Alzheimer disease (AD) is important for clinical management and affords the opportunity to assess potential disease-modifying agents in trials. To our knowledge, this first report a randomized trial prospectively enrich study population with prodromal AD (PDAD) defined by cerebrospinal fluid (CSF) biomarker criteria mild cognitive impairment (MCI) symptoms.To safety γ-secretase inhibitor avagacestat PDAD determine whether CSF biomarkers can identify patient prior...
Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future interventional trials against in would strongly benefit from biomarkers that support diagnosis.To investigate potential novel radiotracer 18F-PI-2620 as biomarker patients with clinically diagnosed PSP.In this cross-sectional study, participants underwent dynamic positron emission tomography (PET) 0 to 60 minutes after...
Post-mortem and neuroimaging studies suggest that the serotonergic system, which originates from brainstem raphe nuclei, is disrupted in Parkinson's disease. This could contribute to occurrence of non-motor symptoms tremor, are only partially explained by dopamine loss. However, level involvement nuclei early disease still debated. (123)I-FP-CIT single photon emission computed tomography a marker serotonin transporter availability. While binds primarily transporters striatum, its binding...
LMTM is being developed as a treatment for AD based on inhibition of tau aggregation.To examine the efficacy monotherapy in non-randomized cohort analyses modified primary outcomes an 18-month Phase III trial mild AD.Mild patients (n = 800) were randomly assigned to 100 mg twice day or 4 day. Prior unblinding, Statistical Analysis Plan was revised compare subgroup 79) versus randomized 396), and 76) add-on therapy 297), with strong control family-wise type I error.The statistically...
ABSTRACT Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes early, untreated PD. Methods: We describe 5‐year the MDS‐UPDRS other measures using results from Parkinson's Progression Markers Initiative, a cohort early disease (PD) participants at baseline. also provide data on 123‐I Ioflupane striatal binding correlation between 2 measures. Results: A total 423 PD were recruited, 358 remain year 5. Baseline score 32.4...
<h3>Importance</h3> Detecting individuals at risk for Parkinson disease (PD) during the prodromal phase could clarify mechanisms and allow treatment earlier in process to possibly slow or prevent onset of motor PD. <h3>Objective</h3> To determine if combination smell identification testing followed by dopamine transporter (DAT) imaging can accurately efficiently identify from general population conversion a clinical diagnosis <h3>Design, Setting, Participants</h3> Participants were...